NCT06093022 Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study
| NCT ID | NCT06093022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 720 participants |
| Start Date | 2018-04-01 |
| Primary Completion | 2024-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 720 participants in total. It began in 2018-04-01 with a primary completion date of 2024-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.
Eligibility Criteria
Inclusion Criteria: * \> 18 years old * BCLM * BCLM and extra-hepatic disease * Any treatment * Ability to understand and sign the informed consent Exclusion Criteria: * Inability to provide the informed consent * Patient who underwent Best Supportive Care or Palliation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06093022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06093022 currently recruiting?
Yes, NCT06093022 is actively recruiting participants. Contact the research team at amelia.mattia01@icatt.it for enrollment information.
Where is the NCT06093022 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT06093022 clinical trial?
NCT06093022 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 720 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.